| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 101.84 | 4.7% |
| Total Income | 102.70 | 4.3% |
| Expenditure | 95.56 | 4.2% |
| PBT | 7.13 | 5.8% |
| Net Profit | 5.33 | 24.8% |
| OPM | 0.18% | 0.51pp |
| NPM | 5.19% | 1.21pp |
| EPS | 11.29 | 24.8% |
Fredun Pharmaceuticals Reports Exceptional Q3 & 9M FY25 Performance, Reports Highest Ever Order Book of Rs. 197 Cr
05 Feb 2025 · 5 Feb 2025, 01:46 am
Summary
Fredun Pharmaceuticals Limited, a leading provider of pharmaceuticals and innovative healthcare solutions, has announced their financial results for the quarter and nine months ended December 31, 2024. The company reported a total income of Rs. 102.7 Cr in Q3FY25, a growth of 18.0% YoY. The EBITDA stood at Rs. 13.2 Cr with an EBITDA Margin of 12.9%. The Profit After Tax (PAT) stood at Rs. 5.3 Cr, a healthy growth of 26.3% YoY. For 9M FY25, the total income stood at Rs. 288.9 Cr, a growth of 25.0% YoY. The EBITDA stood at Rs. 37.7 Cr with an EBITDA margin of 13.0%. The PAT stood at Rs. 13.7 Cr, a robust growth of 30.1% YoY. The company also announced a highest ever order book valued at Rs. 197 crores.
Key Highlights
- 1
Q3FY25 total income stood at Rs. 102.7 Cr, a growth of 18.0% YoY.
- 2
EBITDA at Rs. 13.2 Cr with an EBITDA Margin of 12.9% in Q3FY25.
- 3
Profit after Tax stood at Rs. 5.3 Cr in Q3FY25, a growth of 26.3% YoY.
- 4
Total income stood at Rs. 288.9 Cr for 9M FY25, a growth of 25.0% YoY.
- 5
Highest ever order book valued at Rs. 197 crores.
Management Comments
Mr. Fredun Medhora
Managing Director
We are pleased with our strong growth this quarter and over the nine-month period, reflecting our commitment to innovation and operational excellence. Our strategic initiatives continue to drive momentum, strengthening our position in key markets. A major milestone this year has been the launch of our Advanced Functional Foods Plant in Palghar, Maharashtra, which is set to redefine pet health and nutrition in India. This facility will not just cater to the rising demand in the pet care market but raise the bar for quality and innovation. In addition, the establishment of FREDNA VET DIAGNOSTICS, India’s first advanced diagnostic centre exclusively for pets, highlights our commitment to improving veterinary healthcare with cutting -edge technology and round- the-clock services. On the operational front, the installation of a new Tube Filling Machine will significantly enhance our capacity, nearly tripling our topical production by Q1 FY26. These advancements, along with strategic investments in manufacturing and packaging, position us well for future growth. With a record order book of 197 crores and a revenue visibility of around seven months, we are confident of sustaining this momentum. Our upcoming product launches including protein powder, Chuu Spray & Roll-on, and innovations in the Mobility segment, will further strengthen our portfolio and address evolving consumer needs. This quarter has been one of meaningful progress, and we remain committed to delivering excellence and value to all our stakeholders.
Informational and educational content only. Not investment advice.